Latest research on Insulin detemir

Insulin detemir is a long-acting human insulin analogue used to maintain basal levels of insulin in diabetic individuals. It is produced using recombinant DNA technology in yeast cells. This insulin analogue has a 14-C fatty acid, myristic acid, bound to the lysine amino acid at position B29. The myristoyl side chain increases self-association and albumin binding. This along with slow systemic absorption from the injection site prolongs distribution of the hormone into tissues and results in a long duration of action. Novo Nordisk markets insulin detemir under the trade name Levemir.

Insulin detemir dosage

From September 2010 to July 2012, we enrolled Korean patients aged ≥18 years who had been diagnosed with type 2 diabetes for 6 months according to the 1999 World Health Organization criteria12, had been treated with a stable dose of basal insulin (insulin glargine or Insulin detemir) for ≥2 months, and had a verified HbA1c level between 7.5 and 10.0%. [source, 2015]
In the 26-week extension, a lower insulin dose and a significantly greater reduction in fasting plasma glucose versus Insulin detemir were achieved. [source, 2015]
The logistic regression model identified the following factors as predictors of nocturnal asymptomatic hypoglycemia (each shown with its adjusted OR and 95% confidence interval): HbA1c (per 1% increase in HbA1c), 0.46, 0.25–0.84; total daily dose of insulin (per 1 U/kg increase in total daily dose of insulin), 75.1, 1.65–3418; and insulin glargine (vs. Insulin detemir), 6.93, 1.42–34.0. [source, 2015]
The results showed no significant changes in various parameters of glycemic control, such as fasting plasma glucose, HbA1c, and glycosylated albumin, after switching to insulin degludec despite about 20% reduction in basal insulin dose at 12 weeks, indicating that insulin degludec has longer duration of action and a more potent glucose-lowering effect than insulin glargine or Insulin detemir. [source, 2015]
Whereas insulin glargine typically has a duration of action lasting 24 h or longer, the duration of action for Insulin detemir has been shown to be dose-dependent, ranging from 6 to 24 h [7, 15]. [source, 2015]
A recent study of 973 insulin-naïve patients initiated on either insulin glargine or Insulin detemir for basal blood glucose control compared changes in A1c, the percent of patients reaching A1c goal of under 7 %, and the insulin dose required [8]. [source, 2015]
A second dose was added to the Insulin detemir group only if the pre-dinner plasma glucose levels were elevated. [source, 2015]
Evaluating the number of patients who required an increase in frequency of administration to twice a day dosing after conversion would help determine the actual clinical impact of the proposed dose-dependent differences in duration of action of Insulin detemir. [source, 2015]
In an older, mainly white veteran population with type 2 diabetes, conversion from insulin glargine to Insulin detemir resulted in an increase in A1c post-conversion, decrease in weight and BMI, and an increase in total daily dose. [source, 2015]
Findings of recently published studies [27–29] suggest that the use of insulin glargine is associated with greater glycemic control than Insulin detemir at the same dose. [source, 2015]